Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|February 24, 2015
I Holland’s Metalized Bellows and Drip Cups
Granule contamination during the tabletting process can cause costly manufacturing problems. Punch bellows and drip cups help to prevent tablet and punch guide contamination during the tablet compression process.
Advertisement
I Holland, a leading manufacturer of tablet tooling for the pharmaceutical and nutraceutical industries, has developed a range of metalized bellows and drip cups to help stop costly manufacturing problems caused by granule contamination during the tabletting process.
Punch bellows and drip cups, work by preventing tablet and punch guide contamination during the tablet compression process, forming a seal between the turret and punch barrel. The close proximity of these to the die table may occasionally lead to the inclusion of small fragments of material in the finished tablet. To help in preventing this problem, I Holland has developed bellows and drip cups that are identifiable by standard metal detection equipment. This innovative design means that tiny fragments of material will not reach the end user
All I Holland bellows and drip cups are made from silicone and are 100% Food & Drug Administration (FDA) compliant. The metallized versions are also completely detectable at a size of 2mm x 2mm (tests carried out using an INSIGHT PH metal detector), giving peace of mind that the end tablet will be of the highest standard.
I Holland’s range of metalized bellows and drip cups are offered in a range of sizes. For further information, please contact
Contact Details:
I Holland
Website:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement